THIS IDC MARKETSCAPE EXCERPT FEATURES ACCENTURE

FIGURE 1

IDC MarketScape: Worldwide Life Science R&D ITO Services Vendor Assessment

Source: IDC, 2021

Please see the Appendix for detailed methodology, market definition, and scoring criteria.
IN THIS EXCERPT

The content for this excerpt was taken directly from IDC MarketScape: Worldwide Life Science R&D ITO Services 2021 Vendor Assessment (Doc # US47455021). All or parts of the following sections are included in this excerpt: IDC Opinion, IDC MarketScape Vendor Inclusion Criteria, Essential Guidance, Vendor Summary Profile, Appendix and Learn More. Also included is Figure 1.

IDC OPINION

There has been a significant change in the role of IT service providers in the past one and a half years. From service providers that would support much of the day-to-day IT infrastructure management, the COVID-19 pandemic has caused life science companies to lean on their IT service providers to provide strategic direction in ensuring business continuity during this critical time. The ability to "keep the lights on" has almost become a business-critical need, and those IT service providers that could not meet those criteria during the pandemic have come under the radar, and continuity of these partnerships may now be reevaluated.

The ask, however, has been more than that. The life science industry has looked at IT service providers to transition into being true partners that can provide mindshare in helping them craft their future road map to drive digital resiliency and provide innovative strategies and technologies to help them accelerate growth. As the world adopted a disaggregated care model and "patient centricity" gained critical importance, experience and expertise in implementing decentralized clinical trial solutions and in crafting remote patient engagement solutions have gained importance. The steady shift in focus on real-world data (RWD) from commercial to R&D had heightened the importance of partners that have capabilities in driving electronic data capture (EDC)-electronic health record (EHR) integration. As data has become the new gold, life science companies are now looking at their IT vendors to truly partner with them in helping them think through their strategies around data governance and data acquisition, including answering questions such as whether they should obtain data, or insights, or a data analytics platform, as well as with which companies should they be establishing strategic partnerships. IT service providers are slowly stepping into the territory which once used to be owned purely by strategic consulting companies, as life science companies value the ability of their IT partners to provide them with both the strategic direction and help them with integrating data and technology within existing workflows. Thus it is an interesting time, where IT service providers are seen to be building their strategic consulting portfolio to complement and enhance their IT offerings, while strategic consulting companies are growing their digital and data and analytics footprint.

IT services providers are now exploring newer territories such as in silico drug discovery, drug repurposing, the digitalization of labs to build the lab of the future, and the development of digital twins. The pandemic has brought to the fore the importance of collaboration and co-innovation and has led to the evolution of digital ecosystems. Thus expertise in implementing federated learning platforms and in providing data fabrics that can enable the secure and real-time sharing of data between cross-functional teams serves as a differentiator.

The life science industry, having seen a vaccine being successfully brought to the market in less than a year, is hungry to replicate these models and to accelerate innovation for other therapeutics. Therefore, partners with expertise in integrating robotic process automation (RPA) and AI/ML into their solutions and with well-established partnerships with cloud providers are becoming partners of choice.
Experience in agile implementation strategy has become a necessity, not a "nice to have," as speed and flexibility have become the need of the hour.

While the life science industry seeks IT service providers that can partner with them to provide accelerated and scalable solutions, a lot of the industry is wary about increasing its IT spend right now, given the challenges that the pandemic has posed. Thus the industry is looking for partners that can provide flexible modular solutions that can be rapidly integrated within existing workflows, without requiring significant investment in new platforms and solutions and the need to shelve existing legacy platforms.

The pandemic has served as a wake-up call to the life science industry. As the industry struggled to sustain and recoup, it has taken note of the partners that rapidly moved in to provide support and that made a true difference in these challenging times. One may expect to see a phase of consolidation, as pharma and biotech companies narrow down their partnerships, complementing these with partnerships with some of the many smaller start-ups that leveraged an excellent opportunity to bring in innovative solutions, which were the need of the hour. Thus IT service providers are also moving fast to establish these partnerships themselves to address this need.

While there are routinely a number of vendors with sufficient experience to effectively compete for RFIs, RFPs, and other service requests, it is important for companies to shrink the broad list of prospective vendors to a short list of three to five finalists based on a balanced scorecard that accurately captures specific company requirements and needs. Successful selection of a single (or limited number of preferred) service providers depends on careful consideration of key criteria.

Building on contributions from 11 major life science R&D IT outsourcing (ITO) service providers (including the top 5 vendors by R&D ITO market share), this study examines the life science R&D IT outsourcing vendor landscape today with a view toward expected growth over the next three to five years. This is the third of three IDC MarketScape documents (BPO, ITO, and strategic consulting) examining IT outsourcing in the life science R&D space. When evaluating vendors, the key criteria IDC believes that life science companies should consider include:

- Breadth of life science R&D ITO services offered; depth of related application, platform, and project experience; and number of customers the vendor has served
- Geographical footprint and global delivery capabilities, level of priority and focus by the vendor on the life science R&D sector, and the vendor's pace of investment in related life science-specific capabilities
- Depth of business-related, industry-specific knowledge and the ability to apply this knowledge to improving client performance and success
- Foundational IT service capabilities, corporate financial stability, and ability to accommodate different types and sizes of life science clients
- Diligent vetting of customer references to examine vendor capabilities surrounding project management, IT technical skills, account management, and overall value delivery to clients

**IDC MARKETSCAPE VENDOR INCLUSION CRITERIA**

IDC frequently has unique visibility into vendor selection processes within life science companies through clients and contacts in the industry. For a vendor to be considered for inclusion in this study, the vendor's services must have been significantly evaluated for the potential to engage clients within the target IDC MarketScape space. Further research and due diligence were then conducted to narrow
the list of vendors to only those that IDC views as legitimate contenders for future deals within the life science R&D ITO services space. Eleven life science R&D ITO vendors were selected to participate in this study:

- Accenture
- Atos
- Cognizant
- HCL
- Indegene
- Infosys
- NTT DATA
- Tata Consultancy Services (TCS)
- Tech Mahindra
- Wipro
- ZS Associates

**ADVICE FOR TECHNOLOGY BUYERS**

The pandemic has accelerated growth of IT outsourcing in the life science industry. It has also changed the lens through which the life science industry looks at IT service providers. Priority is being given to those that could ensure seamless business continuity during the time of the pandemic. The next most important criterion is the ability to accelerate innovation by providing strategic direction, complemented by technology implementation. Accountability, demonstrated through risk-sharing and outcome-based pricing models, is another driving factor.

All of these are complemented by the ability of IT service providers to provide solutions that will help them quickly adapt to evolving business models and drive new product development while complying with increasingly complex and growing regulatory compliance requirements. The life science industry is also monitoring the investment in R&D that IT service providers themselves are making to develop innovative solutions in newer areas, as these will be the partners that will provide technologies that will help them differentiate themselves. Hence, IT service providers are also continuously scanning the radar to stay ahead of the curve and build both technology and thought leadership, upskilling their internal teams and upgrading their technology portfolio.

As the life science R&D sector is literally exploding with innovative technologies and implementation models, it has become apparent that partnerships are key. Life science companies are choosing IT vendors that not only have strong internal capabilities, but those that have made the right choices in terms of their strategic partners, so that the partnership with the IT service provider brings compounded value to the table.

In an industry which is not currently interested in making major investments in IT, IT service providers that can provide flexible, modular solutions, agile implementation strategies, and outcome-based pricing models will be partners of choice. In a time of struggle and survival and in an industry that is trying to return to normal, IT service providers should cut the slack, move beyond transactional activities and conventional business models, prove their worth, and truly take their partnerships to the next level. This is an opportunity not to be lost.
In IDC's view of the ITO ecosystem, key attributes that life science companies are looking for in their preferred service providers include:

- The ability to ensure business continuity and drive digital resiliency
- Deep, proven life science-specific ITO capabilities
- An understanding of the life science business at both company and tactical levels
- Flexibility in resourcing on a global basis, including availability of onshore/onsite for some needs and shadow resources to accommodate anticipated attrition
- The ability to effectively scale up engagements in a timely fashion (both onshore and offshore)
- Strong referenceable clients
- Practical understanding of application, platform, and infrastructure best practices that can be quickly translated into engagements to efficiently and effectively develop, maintain, and advance both industry-agnostic and life science-specific data, application, and platform needs

IDC recommends that life science companies also consider the following during their vendor selection include:

- The ability to regionally source external outsourcing resources in emerging regions as life science companies expand globally
- The ability to work effectively with multiple stakeholders (including competing service providers) to drive IT operational efficiency and effectiveness across organizational boundaries
- Emphasis on quality over cost at a foundational level
- The ability to deliver a unified service capability over multiple service or geographical areas
- Commitment to growing partner relationships with companies through investment and flexibility as processes change and evolve
- The potential to seamlessly expand services delivered across the broader business process, IT, and strategic consulting outsourcing landscape as part of preferred vendor relationships
- Compatible corporate cultures
- Established strategic partnerships with key players
- The ability to demonstrate accountability through outcome-based/risk-sharing pricing models

VENDOR SUMMARY PROFILE

This section briefly explains IDC's key observations resulting in a vendor's position in the IDC MarketScape. While every vendor is evaluated against each of the criteria outlined in the Appendix, the description here provides a summary of the vendor's strengths and challenges.

**Accenture ITO**

After a close evaluation of Accenture's offerings and capabilities, IDC has positioned the company in the Leaders category in this 2021 IDC MarketScape for worldwide life science R&D ITO services.

Founded in 1989, Accenture has been serving the life science industry for more than 30 years. The company, headquartered out of Dublin, Ireland, has a presence in 120 countries. Its Global Delivery Network includes 50 delivery centers, with life science spanning 25 offices. Life science represents around 24% of Accenture's Products operating group's revenue and R&D represents about one-fourth
of the same. Life science revenue is expected to grow by 10% in the next three years. Accenture employs more than 500,000 people worldwide, with more than 15,000 specifically dedicated to life science and 5,000 focused on R&D, with an even split between those that are technical and functionally focused. Close to 60% of its life science R&D staff come from the life science industry and has an average industry experience of 15 years. This includes more than 400 medical professionals and 2,500 experts with IT and R&D domain expertise, reflecting Accenture’s strong command over the life science industry. More than 90% of Accenture’s business is derived from companies with revenue over $1 billion, with about one-third of its customers coming from Europe and two-thirds from the United States. Accenture has close to 500 pharma customers, and it works with many medical device companies and a good number of biotechs as well.

**Strategic Initiatives**

Accenture believes that the industry is experiencing gradual compressive disruption, as a result of industry convergence, macroeconomic factors, and other changes. However, Accenture sees New Science (Accenture’s global analysis of regulated scientific treatments), an evolving, unique combination of the best in science and health technology, fulfilling an unmet need and raising the standard of care. Accenture projects New Science driving 81% of biopharma revenue growth and 61% of all biopharma revenues from 2021 to 2026, although it would carry a three to five times higher price tag. The analysis has revealed a 10.8% success rate for New Science compared with 7.2% for other new molecular entities (NMEs) and new biologic entities (NBEs). Accenture believes that New Science will drive industry growth and continually reshape the landscape, and it is investing in new capabilities, talent, alliance, and acquisitions across a range of areas such as digital, mobile, AI, ML, RPA, blockchain, augmented reality, and quantum computing.

Accenture foresees a continued investment in and prioritization of data-driven reinvention and digital R&D transformation and cloud transformation across the value chain. Accenture is growing its data analytics and new product development capabilities, developing proprietary AI/ML-enabled assets, and building capabilities around priority cloud partners and around digitization of lab and clinical trials.

**M&As**

Accenture acquired LabAnswer in 2017, a United States-based research and lab informatics scientific and consulting firm, and Knowledgent in 2018, a data intelligence organization with expertise in clinical data and IT solutions, which contributed significantly to the development of INTIENT. In 2021, Accenture acquired Cirrus, a United Kingdom-headquartered leadership and talent consultancy, with expertise in creating behavioral change and implementing agile ways of working. In 2021, Accenture acquired Future State, a United States-based change management consulting firm, with expertise on agile business transformation, leveraging expert planning, intuitive communication, team coaching and empathy, and expanding Accenture’s C-suite offerings. In 2020, Accenture acquired OpusLine, a Paris-based health consulting company renowned for its strategic advisory and transformational services provided to healthcare organizations in France. In 2020, Accenture acquired Clarity Insights, a United States-based data consultancy, with deep data sciences, AI and ML expertise, and a strong portfolio of accelerators. In 2019, Accenture acquired Enterprise System Partners (ESP), a consulting and manufacturing services provider for the life science industry.

**Pricing Models**

Accenture uses a mix of time and materials, fixed fee outcomes-based, FTE, and managed services arrangements and is seeing an evolution toward outcomes-based pricing. The commercial structure of the larger ITO arrangements frequently includes service-level agreements with fees at risk and tied to
the achievement of agreed-to performance levels. There is an interest in value-based arrangements tied to client business outcomes (e.g., productivity savings, cycle time reductions, or IT cost/rationalization reductions). One-tenth of contracts involve a risk-sharing component.

**Strengths**

Accenture provides expertise in building agile, lean, and digitally enabled business models from early discovery through approval, launch, delivery, full commercialization, and patient services. Accenture is strong in application management (AM) and development (leveraging the MyWizard liquid plug-and-play platform) and in driving AI-driven automation across the SDLC, modern engineering automation, modern operations, and automated self-healing ticketing, complemented by assisted healing and predictive analytics in areas such as product development and business disruption prediction. This is enabling site reliability engineering (SRE) and an "automation in the cloud" way of working and is interweaving IT KPIs with business KPIs, powering Accenture's philosophy of Accenture Living Systems, technology package implementation, and new product development. MyWizard manages over 67,000 tickets per day, has been used to implement over 50,000 automation use cases, and has been used across 9,000 projects for over 1,500 clients, with over 185 patents in intelligent automation.

Accenture leverages new tech (e.g., AI, robotics, ML, quantum computing) and the Accenture Innovation Architecture to accelerate drug discovery and development and patient support as well. Accenture's INTIENT platform is a Google cloud-based open architecture technology platform, powered by Accenture Applied Intelligence, enabling continuity and flow of information across the enterprise. It has four key modules, namely research, clinical, pharmacovigilance (PV), and the patient. Accenture has strong relationships with cloud providers (Google, Microsoft, and Amazon Web Services [AWS]), enterprise software leaders (SAP, MS, Oracle, Salesforce, Medidata, Veeva, LabWare, and PerkinElmer), and niche players such as Medable, RxLogix, and RedCap. Accenture has helped 90% of Fortune 500 Life Science companies deliver improved outcomes to the patients. One-third of Accenture's business is focused on clinical trials; other focus areas include PV, regulatory, preclinical, and discovery.

ITO comprises 50% of Accenture's life science business. Innovation is core to Accenture, and more than 50% of Accenture's business includes an innovation component and 100% includes an intellectual property (IP) component. One of Accenture's most complex projects involved providing global application management services for over 1,500 applications across all major business functions for a top 5, United States-based pharma company, yielding 35% cost reductions over the past six years. Accenture also created an ML-based virtual assistant to support research scientists working on target identification to better predict potential targets for a disease state. In addition to its innovative architecture and its life science and technology expertise, customers also value the access to the Accenture Life Sciences Coalition, a pharma consortium of Accenture's customers, enabling mindshare on key topics. To quote a leading global pharma, "I always felt I was in great company, strong leadership, and very skilled people."

**Challenges**

Accenture should continue to expand and customize its offerings to make the company more attractive to emerging and midsize companies. From a service offering perspective, ITO services positioned for further development by Accenture include predictive modeling, biostatistics, and identification of medicinal products (IDMP).
APPENDIX

Reading an IDC MarketScape Graph

For the purposes of this analysis, IDC divided potential key measures for success into two primary categories: capabilities and strategies.

Positioning on the y-axis reflects the vendor’s current capabilities and menu of services and how well aligned the vendor is to customer needs. The capabilities category focuses on the capabilities of the company and product today, here and now. Under this category, IDC analysts will look at how well a vendor is building/delivering capabilities that enable it to execute its chosen strategy in the market.

Positioning on the x-axis, or strategies axis, indicates how well the vendor’s future strategy aligns with what customers will require in three to five years. The strategies category focuses on high-level decisions and underlying assumptions about offerings, customer segments, and business and go-to-market plans for the next three to five years.

The size of the individual vendor markers in the IDC MarketScape represents the market share of each individual vendor within the specific market segment being assessed.

IDC MarketScape Methodology

IDC MarketScape criteria selection, weightings, and vendor scores represent well-researched IDC judgment about the market and specific vendors. IDC analysts tailor the range of standard characteristics by which vendors are measured through structured discussions, surveys, and interviews with market leaders, participants, and end users. Market weightings are based on user interviews, buyer surveys, and the input of IDC experts in each market. IDC analysts base individual vendor scores, and ultimately vendor positions on the IDC MarketScape, on detailed surveys and interviews with the vendors, publicly available information, and end-user experiences in an effort to provide an accurate and consistent assessment of each vendor’s characteristics, behavior, and capability.

Market Definition

For the purposes of this study, ITO includes outsourcing of all IT services, including integration of IT solutions, app development and maintenance, application portfolio rationalization, infrastructure management, consulting and package implementation services aligned to business imperatives, and support from data governance, IT security, cloud implementation, and intelligent automation solutions.

Market Overview

A turbulent year and a half had the life science industry dealing with the suspension and the discontinuation of multiple clinical trials and had businesses coming to a staggering halt. This is where IT service providers have differentiated themselves, have worked round the clock, and have come up with innovative technologies and business models to help their life science customers ensure business continuity, roll out new clinical trials, and accelerate innovation to bring new therapies and vaccines to the market at a speed unheard of before. The IT service providers have helped their life science customer successfully implement decentralized clinical trials, complemented by the use of the Internet of Medical Things (IoMT) and telemedicine, while developing innovative solutions to ensure continued patient engagement in a remote, disaggregated care model. Undoubtedly, all of this has been enabled by the support of regulators across the globe.
While patient expiries and the loss of blockbuster drug revenue were the key drivers in the past, the newer drivers referenced previously have resulted in IT service providers being looked at through a different lens. The life science industry is no longer looking only for tactical support and externalizing noncore competencies, but is looking for partners, that can bring in true thought leadership and innovative solutions, to drive business agility. As the borders between life science and healthcare are blurring, and connected health gains increasing importance, the life science industry is looking for partners that can help it connect the dots and develop more holistic solutions, providing a complete view of the patient across not only the continuum of care but the continuum of research and care.

With data becoming the new currency, insights are defining the new net worth of an organization and life science companies are leaning on their IT partners to help them navigate the path. As the industry attempts to figure out its cloud strategy, its data governance models, and its digital transformation road map, IT service providers have an increasingly important role to play. As the life science industry remains hungry to recover and grow, one has seen the growth of digital ecosystems and the use of federated learning platforms and regulatory-compliant collaborative IT infrastructure to fuel co-innovation.

The industry is rapidly exploring the use of AI/ML, NLP, computer vision, and AR/VR to transform R&D. High-performance computing is gaining increasing importance, and the ability of GPU-powered transformer models and the use of digital twins to exponentially accelerate in silico drug discovery will disrupt the industry. IT service providers that have acquired expertise in these technologies and have the appropriate partnerships will lead the way.

While ensuring digital resiliency and driving accelerated innovation remain the key objectives of this industry, the life science industry is still keeping a cautious eye on budgets. While it may move toward vendor consolidation, it is going to look for cost-effective and modular solutions that can be easily integrated within existing workflows.

Key R&D areas where ITO services have expanded include in silico discovery, the use of digital twins, regulatory compliance and intelligence, the increased importance of RWE in R&D, expertise in decentralized clinical trial solutions and telemedicine, and expertise in strategy and technology to support M&As. Areas anticipated for ITO growth will likely include AI/ML-enhanced ITO solutions, remote patient monitoring solutions, and RWE and regulatory-compliant collaborative IT infrastructure.

IDC expects that when combined with BPO and strategic consulting services, the total IT services market will continue to grow at double-digit rates over the next five years, across the entire life science R&D value chain.
Related Research

- **IDC MarketScape**: Worldwide Life Science R&D Strategic Consulting Services 2021 Vendor Assessment (IDC #US48159321, forthcoming)
- **IDC MarketScape**: Worldwide Life Science R&D BPO Services 2021 Vendor Assessment (IDC #US48126821, August 2021)
- **IDC Health Insights**: Knowledge-Based Medicine Digital Transformation in Life Sciences, July 2021 (IDC #US48069421, July 2021)
- **Leveraging Telehealth to Accelerate Clinical Trials** (IDC #US48024721, July 2021)
- **The Future of Intelligence for Life Sciences: Transcending Boundaries** (IDC #US47730821, June 2021)
- **GPU-Powered Transformer Models Poised to Accelerate Drug Discovery and Disrupt Drug Development** (IDC #US47660321, May 2021)

Synopsis

This IDC study is the third of a three-part life science R&D IDC MarketScape series focused on IT outsourcing. With a specific focus on life science R&D ITO, this document seeks to compare major IT service providers with each other, based on operational, business, and market-centric criteria that should be important to life science companies when considering the selection of an external service provider to take over noncore IT activities. IDC MarketScape assessment of IT outsourcing in life science R&D was previously performed in 2011, 2013, 2015, and 2018.

Dr. Nimita Limaye, research VP, Life Science R&D Strategy and Technology at IDC, noted, "The COVID-19 pandemic has brought to the fore the importance of the ITO service providers to the life science industry. Their role has transitioned beyond that of serving as tactical providers to that of strategic partners that will help steer the implementation of agile innovation models, drive digital resiliency, and fuel accelerated business growth. It is for the ITO service providers to build their internal capabilities, strengthen their digital ecosystems, and provide both the technology and the mindshare that will help them truly leverage this momentous opportunity."
About IDC

International Data Corporation (IDC) is the premier global provider of market intelligence, advisory services, and events for the information technology, telecommunications and consumer technology markets. IDC helps IT professionals, business executives, and the investment community make fact-based decisions on technology purchases and business strategy. More than 1,100 IDC analysts provide global, regional, and local expertise on technology and industry opportunities and trends in over 110 countries worldwide. For 50 years, IDC has provided strategic insights to help our clients achieve their key business objectives. IDC is a subsidiary of IDG, the world’s leading technology media, research, and events company.

Global Headquarters

140 Kendrick Street
Building B
Needham, MA 02494
USA
508.872.8200
Twitter: @IDC
blogs.idc.com
www.idc.com

Copyright and Trademark Notice

This IDC research document was published as part of an IDC continuous intelligence service, providing written research, analyst interactions, telebriefings, and conferences. Visit www.idc.com to learn more about IDC subscription and consulting services. To view a list of IDC offices worldwide, visit www.idc.com/offices. Please contact the IDC Hotline at 800.343.4952, ext. 7988 (or +1.508.988.7988) or sales@idc.com for information on applying the price of this document toward the purchase of an IDC service or for information on additional copies or web rights. IDC and IDC MarketScape are trademarks of International Data Group, Inc.

Copyright 2021 IDC. Reproduction is forbidden unless authorized. All rights reserved.